We work relentlessly to solve the most difficult challenges faced by people affected by rare diseases.
Enzyvant is a biopharmaceutical company that is driven to make a life-altering impact for people affected by rare diseases.
With a first-of-its-kind FDA approval in regenerative medicine and promising advances against some of the greatest challenges in immunology and cardiopulmonology, Enzyvant is accelerating the transformative medicines urgently needed by the rare disease community.